Fosun International Ltd. (00656:HK) and London-based healthcare and life science company Arix Bioscience plc (LSE:ARIX) have jointly announced a strategic agreement to develop and commercialize new clinical therapies for patients with a focus on the Chinese markets.
Citic Capital-controlled Harbin Pharmaceutical Group Holding, known as Hayao, has agreed to invest US$300 million in U.S.-based health and wellness retailer GNC Holdings, becoming the single largest shareholder in NYSE-traded GNC.
American nutrition supplements company Herbalife Ltd. announced today it has created a “China Growth and Impact Investment Fund” to accelerate growth of its business in China.
U.S. pharmaceutical giant Pfizer has taken a financial stake and entered into a two-year research collaboration with NetVation DL Medicine, a privately held biotechnology company that is backed by Chinese Academy of Sciences.
Ping An Healthcare And Technology Co., Ltd., which operates the popular healthcare and medical mobile app Ping An Good Doctor, has been cleared for a US$5 billion initial public offering in Hong Kong.
Ping An Ventures, the direct investment arm of Ping An Insurance (Group) Company of China, Ltd., has led a US$100 million series A round in Philadelphia-based biotherapeutics company Tmunity Therapeutics.
Chinese investment banking firm CEC Capital Group has announced the promotion of John Song, Gang Li and Zack Zhang to partner, as the firm aims to broaden and deepen its coverage to a new class of rising Chinese enterprises.
Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences Co., Ltd., a Chinese biopharmaceutical company.
Chinese private equity firm C-Bridge Capital has teamed up with Suzhou bio-medical and medical high-tech park BioBAY in leading a US$38 million series A round in CMAB BioPharm, a contract development and manufacturing organization (CDMO) providing comprehensive pharmaceutical services to biopharma companies.
Vision Plus Capital, a Hangzhou-based venture capital firm, has led a RMB200 million (US$30 million) series B round in Etong Healthcare, a third-party health examination service provider.
Ping An Capital, the core equity investment platform of one of the largest Chinese insurers Ping An Insurance Group, has led an over RMB800 million (US$121 million) investment deal in Fullerton Healthcare Corporation Ltd., a Singapore-based provider of corporate healthcare solutions across Asia Pacific, according to an announcement issued by Fullerton Healthcare.
Preceptis Medical Inc., a U.S.-based pediatric surgical technologies developer, has reached the initial closing of its series B financing round led by a group of unnamed Chinese private investors.
SDIC Venture Capital Management, a subsidiary of State Development & Investment Corp (SDIC), has led a new funding round worth up to RMB507 million (US$76 million) in Zensun (Shanghai) Sci & Tech Co., Ltd., a biopharmaceutical company listed on the ChiNext board in Shenzhen.
Chinese healthcare-focused investment firm 6 Dimensions Capital and Sijia Jianxin Fund have led a US$28 million series B round in AnchorDX Corp., a Guangzhou city-headquartered precision medicine start-up.
Dah Chong Hong Holdings Ltd., a Hong Kong-listed distributor and dealer of motor vehicles in Greater China, said it plans to partner with its parent company that is a subsidiary of CITIC Ltd. to establish an investment fund to back consumer and healthcare companies.
China’s healthcare sector is seeing a flood of new capital from from non-professional investors such as Chinese coal mining and factory bosses, according to James Huang, a managing partner at Kleiner Perkins Caufield & Byers (KPCB) China, who focuses on life sciences. As a result, valuations have become excessive, forcing more experienced investors to adopt new strategies to get ahead of the "dumb money."
XW Laboratories Inc., a Chinese biopharmaceutical research and development company focused on neurological disorders, has raised US$17.5 million in a series B financing led by Elements Capital and WI Harper. New investo KTB Network, and all existing investors KPCB China, Johnson & Johnson Innovation and WuXi Venture, also participated.
Chinese biopharmaceutical company Zai Lab Ltd., backed by Chinese venture capital firms including Advantech, OrbiMed Asia Partners and Qiming Venture Partners, has completed an initial public offering on the NASDAQ in New York, raising approximately US$150 million in total.
China Healthcare Investor Forum 2017, hosted by China Money Network and sponsored by Ernst & Young, was successfully held on September 19 at the Shanghai World Financial Center with four prominent speakers discussing investment opportunities and challenges in China’s booming healthcare sector.
Healthcare-dedicated investment firm OrbiMed has closed its third Asia-focused private equity fund, OrbiMed Asia Partners III, LP, with approximately US$551 million in capital commitments.
Eight Roads Ventures has launched its first dedicated China healthcare fund in a move that reflects continued focus of healthcare investments by Chinese venture investors.
Tencent Holdings Ltd. and BlueRun Ventures have led a RMB160 million (US$24 million) series A round in Shuidi, a crowdfunding platform within Tencent’s WeChat mobile app that helps people gain financial assistance to cover healthcare bills.
Chinese private equity firm Yunfeng Capital, co-founded by Alibaba’s chief Jack Ma, has led a RMB190 million (US$29 million) series C round in Kaistart, a Chinese restaurant and hospitality industry-focused crowdfunding platform. Chinese investment firm Certain Capital also participated.
The GTJA Investment Group has led a RMB300 million (US$45 million) series B round in Akeso Biopharma, a Chinese innovative biotechnology company.
Private clinic franchise Distinct Healthcare has raised a US$40 million series C round from Matrix Partners China, Tiantu Capital, China International Capital Co., Ltd, Qianhai Fund of Funds, and Shuimu Fund.
Shanghai-based biopharmaceutical company Zai Lab, founded by Samantha Du, a former managing director at Sequoia Capital, has filed to raise up to US$115 million in an initial public offering on the NASDAQ.
Antengene Corporation, a Chinese clinical-stage biopharmaceutical company, has raised US$21 million in a series A financing round led by Qiming Venture Partners. Chinese investment firms TF Capital and HG Capital, as well as Tigermed Investment, also participated in the deal.
Lilly Asia Ventures, a healthcare-focused venture capital firm backed by global pharmaceutical giant Eli Lilly & Co., has closed its fourth healthcare fund at a US$450 million hard cap.
C-Bridge Capital, a Shanghai-based private equity firm focused on China’s healthcare sector, has closed its second healthcare fund, C-Bridge Healthcare Fund II, at a US$400 million hard cap.
An investor consortium including CICC Qianhai Development (Shenzhen) Fund Management, CITIC M&A Fund Management Co., Ltd., and a number of Chinese bio-industry companies and investment firms, has agreed to privatize NASDAQ-listed Chinese biopharmaceutical products provider Sinovac Biotech Ltd., at the valuation of around US$401.8 million.
Kevin Chen (pictured), a healthcare partner at Sequoia Capital China, has left the firm to start his own healthcare-focused investment fund, someone with direct information of the matter told China Money Network.